Japan’s Ministry of Health, Labor and Welfare (MHLW) on March 5 unveiled the revised NHI prices for drugs subject to…
HOME > TOP STORIES
TOP STORIES
-
ORGANIZATION Kichiro Matsumoto Elected as New Chief of Japan Medical Association
June 27, 2022
-
BUSINESS 25 Japan Drug Makers Log Combined 10.7% Growth in FY2021, 12 See Two-Digit Jumps: Tally
June 24, 2022
-
REGULATORY Japan Shelves Decision on Shionogi’s COVID Pill with Experts at Odds, Another Session Likely Next Month
June 23, 2022
-
BUSINESS Biosimilars Likely to Gain Further Impetus from Govt Push; Forteo/Enbrel Hit 40% Share, Herceptin 50%-Plus
June 22, 2022
-
REGULATORY Kazuhiro Oshima Tapped as Vice Health Minister, Katsufumi Jo as First Councilor for Pharma Industry Promotion
June 22, 2022
-
REGULATORY Japan Approves Janssen’s COVID Jab, Sanofi’s Sutimlimab, Olumiant’s Alopecia Use and More
June 21, 2022
-
BUSINESS Astellas Workforce Down by More than 700: Securities Report
June 21, 2022
-
BUSINESS PeptiDream Set to Develop Peptide-RI Conjugates for Refractory Cancers, Eyes No. 1 Spot in Radiotherapy
June 20, 2022
-
REGULATORY As Election Campaigns Begin, Parties Pitch Policies to Bolster Drug Development, Supply Chains
June 17, 2022
-
BUSINESS Patent Rows Don’t Stop Generic Players; Single Entries, AG Non-Launches Seen in June Listing
June 17, 2022
-
REGULATORY Feburic, Samsca, and More Face First Generics in June Listing, No Xarelto/Eylea AGs
June 16, 2022
-
REGULATORY Kishida Officially Unveils Plan to Form Pandemic Response Agency, Japan CDC
June 16, 2022
-
REGULATORY Shionogi’s COVID Pill Up for PAFSC Review for 1st Emergency Approval
June 16, 2022
-
REGULATORY Japan to Create Expert Panel to Ponder Drug Distribution and Pricing: Kanmin Taiwa
June 15, 2022
-
REGULATORY Japan to Launch New Agency for Pandemic Responses, Eyes MHLW Rejig
June 15, 2022
-
BUSINESS Authorized Generics Gain Ground amid Quality Woes, Candesartan AG Share Up 10 Points
June 14, 2022
-
REGULATORY MSD’s Two-Time PMP Appeals for Lyfnua Rejected: DPO Minutes
June 14, 2022
-
ORGANIZATION FPMAJ Pushes Minimal Product Scope for Off-Year Re-Pricing, No Cut in 2% Buffer Zone: Annual Report
June 13, 2022
-
REGULATORY “Re-Do” Pricing Based on New Assumption Rather than Simple Cuts, DPP Lawmaker Says on Re-Pricing Rules
June 10, 2022
-
BUSINESS Idorsia Japan Set to File Its 2nd and 3rd Drugs Early Next Year, Eyes 80 Billion Yen Sales in 5 Years
June 9, 2022
ページ
Japan’s pharmaceutical industry could be on the verge of gaining a stronger voice in the Central Social Insurance Medical Council…
Let’s face it: in today’s world, changing jobs is a normal part of a successful career. But if it’s so normal, why does it feel so hard? For many people, the idea of leaving their current role brings a heavy…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…